Several works described MDM2 amplification in 7% human solid tumor, such as liposarcoma (50%–90%), osteosarcomas (16%), esophageal carcinomas (13%), and NSCLC (6%) [37]. This evidence concerns the gene MDM2 and carcinoma of esophagus.